Perinatal DeathNCT03729089
Third Trimester Modified Biophysical Profile Scan for Predicting Fetal Outcome.
A study testing Modified Biophysical Profile scan in people with Perinatal Death and Third Trimester Modified Biophysical Profile Scan, run by Dr Andrew Odur at 1 site in Uganda.
Trial summary
Study topic: Predicting fetal outcome using third trimester modified biophysical profile (BPP) scan compared with standard of care; a randomized clinical trial at St. Francis Hospital, Nsambya. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Perinatal Death, Third Trimester Modified Biophysical Profile Scan
- What is being tested?
- Modified Biophysical Profile scan
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 198 participants
- Where
- 1 siteUganda
- Study dates
- 1 Nov 2018to 29 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Viable singleton pregnancy
- Gestational age between 34 to 40 weeks based on reliable date of onset of last normal menstrual period or earliest dating by ultrasonography.
- Willing to be followed up
Who cannot join
- Mother with diagnosed fetal malformations
- High-risk pregnancies (Hypertensive disorders of pregnancy, Diabetes mellitus, multiple pregnancies, Sickle cell disease, Heart disease).
- Inability to consent (e.g. psychiatric conditions or very ill requiring hospitalization).
- Intrauterine fetal death in the current pregnancy
- Presently ill with a medical condition requiring admission to hospital
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predicting Fetal Outcome Using Third Trimester Modified Biophysical Profile Scan Compared to Standard of Care; an Open Label Randomized Controlled Trial at St. Francis Hospital Nsambya.
Study topic:
Predicting fetal outcome using third trimester modified biophysical profile (BPP) scan compared with standard of care; a randomized clinical trial at St. Francis Hospital, Nsambya.
Read more
This is an open label randomized clinical trial comparing the third trimester modified biophysical profile done between 34 to 40 weeks with the current standard of care in reducing perinatal mortality at St. Francis Hospital, Nsambya
Objectives of the study:
Broad study objectives:
To evaluate the role of third trimester modified biophysical profile scan in predicting fetal outcome among pregnant mothers at St. Francis Hospital, Nsambya.
Specific study objectives:
- To determine the percentage decline in perinatal mortality following use of third trimester biophysical profile from 34 to 40 weeks at St. Francis Hospital, Nsambya.
- To determine if use of third trimester BPP scan improves prediction of perinatal outcome more than the current standard of care at St. Francis Hospital, Nsambya.
- To determine the fetal outcome of pregnancies done modified BPP and those who received current standard of care at St. Francis Hospital, Nsambya.
Hypothesis:
The hypothesis of the study is that performing third trimester modified biophysical profile scan between 34 and 40 weeks compared to standard of care is associated with a 16 percent reduction
Read the detailed description
Randomization:
Eligible participants will be randomly allocated to one of the two study groups (modified biophysical profile scan arm or current standard of care arm) by an independent statistician who will not be involved in data analysis. The independent statistician will generate a randomization register consisting of the sequential study numbers but without the allocated study group. The register will be held at the enrollment clinic and patients who will be eligible for enrollment will be assigned the next available number on the register until the required sample size is reached. The principal investigator will identify a secure room from where opaque envelopes containing the different study arms will be kept. Participants will pick envelopes randomly from the pool of envelopes to obtain the study arm to which they automatically belong.
Blinding:
The study will be open label but only blinding the allocation at study entry.
Randomization concealment
No one including the independent statistician will know the study arm at the point of randomization. Because the intervention is not blinded, the rest of the study team including the principle investigator will get to know the study arm after the women have been randomized.
Sample size:
The use of fetal biophysical profile has been associated with 61 to 79 percent reduction in fetal mortality and morbidity. The incidence of perinatal death (Macerated still birth, Fresh stillbirth \& Early neonatal death) in 2016 was 2% of the annual total deliveries, giving a perinatal mortality ratio of 20 per 1000 live birth at St. Francis Hospital Nsambya. The following assumptions will be made in the determination of the minimum sample size; the current standard of care of mothers attending antenatal care at Nsambya Hospital as defined by World health organization (WHO) in 2016 will detect up to 79% of fetal outcome, while performing modified biophysical profile scan proposed in this trial will increase this proportion to 95% at the 5% level of significance, and power of 80. Using a formula for comparing two proportions from Medical statistics book by Betty Kirkwood and Jonathan Sterne, 2003; The minimum sample size , Where this gives an increase in prediction of 16%. V= the Standard normal deviate at 95% Confidence (from Z-statistical tables, V=1.96), U =Standard Normal Deviate at 80% Power (power =1-β) ( from Z-statistical tables, u=0.84). Substituting, = 89.2 women. This gives approximately 90 women in each group and a total sample size of 180 women. Assuming a non-response proportion of 10%, the sample size will be increased by 10% to 198 women (99 in each group).
Data management and handling:
The study data will be entered using Microsoft (MS) access (MS-ACCESS, 2016) and will be double checked and validated before being uploaded into the database. The data entry screens will incorporate a number of range checks and logical skips as appropriate. Data stored in the database will be checked for missing or unusual values (range checks) and checked for consistency within participants. If any such problems are identified the problematic questionnaire will be returned to the clinic for checking and confirmation or correction, as appropriate. The amended version will be returned to the data entrant for correct entry into the database.
Statistical analysis plan:
Participant socio-demographics and other characteristics will be summarized using counts and percentages and by study group, for categorical variables and means and standard deviation for continuous variables. The analysis will be by intention to treat (ITT). I will calculate the mortality rate as the number of death divided by total time of follow up. The mortality will be further stratified by the study group (intervention vs standard of care). Rate ratio comparing the trial groups will be estimated by fitting a cox regression model. If there are any imbalance in the important participant characteristics at baseline, adjustment for these will be performed by fitting cox regression models. A similar analysis will be performed for the secondary outcomes.
Data quality control:
The study team will be trained on data collection and handling procedures. A pretest in form of completing the study questionnaire as well as a dry run will be done before the commencement of the actual data collection. To ensure proper data management, the data collectors will be trained in data management and will complete certification process of Good Clinical Practices (GCPs). Data collectors will be health workers who work in the Obstetrics department, they will not be directly involved in the management of mothers in Antenatal clinic or inpatient wards to avoid observation bias if he/she was among the people managing these patients. All interviews will be conducted in the language understood by the study participants.
Data monitoring committee:
There will be a data monitoring committee established to monitor the quality of data being collected. This three member committee will be selected from outside the study site. They will be people with experience in monitoring trial data. They will sit every 3 months or as requested by the institutional review board of St. Francis Hospital Nsambya.
Data protection and confidentiality:
The study questionnaires will not bear participant names but rather identification numbers. The study team will ensure the data is not accessible to anyone else by 1) keeping the paper questionnaires under lock and key 2) using passwords to secure the study database. The team will also ensure that the study data is used for only the purpose approved by the ethics committees.
Ethical considerations:
The study will seek ethical approvals from the Institutional Review Board (IRB) of Nsambya Hospital. The Hospital authority will also be requested for permission to have access to the pregnant women in the study clinic. Participants will be allowed to withdraw from the study whenever they so wish. All the data collected will be treated with utmost confidentiality.
STANDARD OPERATING PROCEDURE (SOP) FOR ENROLLMENT/SCREENING VISIT
- The pregnant women are received, welcomed and briefed about the services by the midwife in the Antenatal clinic registration desk.
- The midwife registering at the reception will identify pregnant women who are between 34 to 40 weeks gestation.
- If one is attending for the first time but within the gestational age of interest, then the base line investigations will be done (Complete blood count, blood grouping, HIV, Urinalysis, Gestational diabetes mellitus screening, Syphilis test and Hepatitis B test).
- For those who have been booked already, the study midwife will check the antenatal card and results of the above. If any is missing, a request would be written and sample taken.
- Body weight and blood pressure will be measured at this point.
- Immediately after receiving the antenatal card, the pregnant women will be directed to the waiting area from where routine antenatal health education and information about the study is given by one of the Antenatal clinic and study Midwives.
- After providing information about the study, the study midwife will duly consent the mother and assign the randomization number sequentially from the register to those who volunteer to participate in the study.
- The pregnant mother is accompanied by midwife to the study office (Room 9) from where the PI will request the mother to randomly pick an opaque envelope from the randomization pack to determine the study arm of this study participant.
- The study arm will be known by the study team at this point and clearly documented in the patient's antenatal card.
- The enrolled mothers will be examined by the study doctor or midwives and findings documented in the Antenatal card and Case report form (CRF).
- The mothers in the modified Biophysical profile ARM will be required to undergo a modified biophysical profile scanning free of charge and the results of the scan documented in the CRF.
- The mother will bring back the results of the scan and blood tests to the study doctor. The study doctor will document the above results on the CRF. He will give an appropriate follow up date and indicate the date for performing the next modified biophysical profile (mBPP) scan.
- The registers and all other documents are taken to the research office at the end of the day by the Clinical Trial Midwife. All completed CRFs are scrutinized by the Trial PI and signed. If the Trial midwife detects errors in the CRFs, He or she will put a Note to the file accordingly as per the data management SOP.
- The completed file folders will then be placed in the rack for not entered data. The entry into the data base will then be as per the data management SOP.
STANDARD OPERATING PROCEDURE FOR MISSED VISITS
- The pre-enrollment and enrollment registers will have the scheduled appointments for each study participant.
- Any study participant who fails to honor an appointment will be followed up with a phone call the next day to ascertain the reason why she did not turn up and encouraged to come. If she fails to turn up, a second phone call will be made and another appointment fixed.
- A study participant who fails to honor her appointments and fails to respond to the above follow up would be considered as one lost to follow up.
STANDARD OPERATING PROCEDURE FOR TRACING MOTHERS WHO HAVE GONE PAST THEIR EXPECTED DATE OF DELIVERY (EDD) / DELIVERED ELSEWHERE
- Each week, mothers who have not delivered at the study site are traced from the CRF/date of delivery list by the principle investigator.
- The study participant is given a phone call and advised to visit the study site if not delivered to see the Doctors to assess her and plan for her delivery. If the person has already delivered from elsewhere, information regarding delivery is obtained and entered into the CRF.
STANDARD OPERATING PROCEDURE FOR UNSCHEDULED VISIT
- Participants will be encouraged to come in every time they have a problem direct to Antenatal clinic Room 9 or labor ward in case it's after 5.00 pm where a doctor reviews her and the clinical trial coordinator is informed.
- Participant will be seen by the Clinical Trial Investigator in the Antenatal Clinic on Monday- Friday from 8:00am-5:00pm.
- After 5:00pm, during weekends, public holidays, Participant will report to the Labor ward and be seen by the Doctor on Duty and managed appropriately.
STANDARD OPERATING PROCEDURE FOR DOCUMENTING DELIVERY AND FETAL OUTCOME
- Identification of study Participants who present in labor ward will be done by any of the labor ward midwives by asking for their antenatal card bearing the sticker and by asking whether the participant has been in the study. This process will be for both mothers in labor and those scheduled for Cesarean section.
- The labor ward midwives will then inform one of the research midwives about the study participant. The research midwife will then verify the antenatal records and place an appropriate sticker on the patient file for easy identification. The study midwife will duly inform the Principle investigator.
- For mothers who will undergo an elective or emergency cesarean section, the birth outcome will be documented from the post natal wards.
- Immediately after delivery of the baby, the study midwife will document the birth outcome in the CRF which placed in a box file awaiting data cleaning and entry.
- The above procedure will be followed for delivery during day, night and over the weekend.
STANDARD OPERATING PROCEDURE FOR DATA MANAGEMENT
- The Case report form (CRF) will be assessed by the Clinical Trial Principle Investigator daily for accuracy, legibility and completeness.
- The CRFs will then be filled, placed in the respective file folder and then placed in the rack for not entered data.
- Only authorized study staffs (the Data Clerks, Principal Investigator, statisticians) are allowed to have access to the database.
- Every afternoon, the Data Clerk will pick the CRFs from the box file of not entered data and then enter it into the database (Epi-data)
- At the end of the day, all data will be saved and backed up on a flash disk or External Hard Drive.
- After the CRFs have been entered into the database, they will be placed in the Box file for entered data for proper storage by one of the Data Clerks.
STANDARD OPERATING PROCEDURE FOR COMPLETING CASE REPORT FORM (CRF)
- CFR must be filled with a ball-point-black ink.
- Capital letters must be used in all entries of the CRF. The dates that are not known will be represented with value 11/11/1111.
- The Principle investigator and the Trial Coordinator will write Not applicable on all different CRF for non obtainable information whether numerical or non numerical.
- Corrections on CRF will be done by the person who has filled in that CRF.
- Corrections will be done by crossing out the wrong entry with a single line, then writing the correct entry alongside/above/under the wrong entry.
- After correction, a date will be placed alongside the correction as well as the initials of the Research staff.
- A note to file will be placed on that page of the CRFs to explain the correction by the Research staff and confirmed by the Principal investigator
- Being tested
- Modified Biophysical Profile scan
- Medical subject headings
- Perinatal Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Modified Biophysical Profile scanOther
Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
| Study group | Role | What they receive |
|---|---|---|
| Modified Biophysical Profile scan | Experimental | Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea. Receives: Other: Modified Biophysical Profile scan |
| Current standard of care | No intervention | The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Perinatal death
Reduction in the proportion of perinatal death will be measured for the two arms of the study to ascertain whether modified biophysical profile can predict perinatal mortality. Perinatal mortality will be measured as death of the new born within the first 7 days of life. The gestational age considered is after 28 weeks of amenorrhea consistent with the health system capacity of the host country and the study hospital
Measured: At delivery of the newborn
Secondary outcomes (3)
APGAR score
The APGAR score is a clinical score used to assess well being of all newborns. The clinical features of newborn colour, Respiration, Heart rate, muscle tone and reflex stability depends on the aetiology, intensity and duration of oxygen lack, plasma carbondioxide excess and subsequent acidosis. The score will be taken at 1 minute and at 5 minutes after birth and documented in the case report form. Minimum score is 0/10 while the maximum is 10/10. A score of less than 3/10 at 5 minutes indicates severe birth asphyxia; a score of 4/10 to 6/10 signifies moderate asphyxia and 7/10 to 10/10 is a normal new born. The higher the score, the better the neonatal outcome.
Measured: at birth
Neonatal intensive care unit (NICU) admission
The neonatal intensive care (NICU) admission of the newborn will be documented as yes or no at birth. This will be assessed by documenting the post delivery decision of the attending health worker on whether the baby needs NICU admission or not
Measured: Immediately after birth
Cesarean section due to fetal condition
Cesarean section (C/S) performed for fetal conditions will be assessed by the study team by looking out for the indication of C/S and document if it was done due to fetal conditions like non reassuring fetal status, meconium stained liquor, severe oligohydramnios, cord accidents and abnormal fetal heart pattern.
Measured: At delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2018
- Study start1 Nov 2018
- Primary completion1 Mar 2019
- Study completion29 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Perinatal DeathStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Eligible pregnant women at 34 to 40 weeks gestation will be randomized to interventional group (Biophysical profile scanning) or to a control group receiving the current standard of care
- Masking
- None (open label)
- Enrolment
- 198 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Andrew Odur
- Sponsor type
- University, hospital or other
- Collaborators
- Uganda Martyrs University, St. Francis Hospital Nsambya, Jerusalem IHS and Andrew Abaasa (Study statistician)
- Responsible party
- Sponsor-investigator, Dr Andrew Odur, St. Francis Hospital Nsambya
- Investigators
- Andrew Odur, MBChB, DPPM, Principal investigator, St. Francis Hospital NsambyaRomano Byaruhanga, MMed, PhD, Study chair, St. Francis Hospital NsambyaRita Nassanga, MMed, Study chair, St. Francis Hospital NsambyaGilbert Tumwine, MMed, MPH, Study chair, St. Francis Hospital Nsambya
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03729089
- Sponsor's protocol ID
- BPP-NSA-001
- Status last verified
- Apr 2019
- First submitted
- 29 Oct 2018
- Last updated
- 4 Apr 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Only data necessary for publication will be shared
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predicting Fetal Outcome Using Third Trimester Modified Biophysical Profile Scan Compared to Standard of Care; an Open Label Randomized Controlled Trial at St. Francis Hospital Nsambya.
- ClinicalTrials.gov ID
- NCT03729089
- Acronym / sponsor ID
- BPP-NSA-001
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 198 participants (actual)
- Lead sponsor
- Dr Andrew OdurUniversity, hospital or other
- Collaborators
- Uganda Martyrs University, St. Francis Hospital Nsambya, Jerusalem IHS and Andrew Abaasa (Study statistician)
- Study start
- 1 Nov 2018 (actual)
- Primary completion
- 1 Mar 2019 (actual)
- Study completion
- 29 Mar 2019 (actual)
- First posted
- 2 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study topic:
Predicting fetal outcome using third trimester modified biophysical profile (BPP) scan compared with standard of care; a randomized clinical trial at St. Francis Hospital, Nsambya.
This is an open label randomized clinical trial comparing the third trimester modified biophysical profile done between 34 to 40 weeks with the current standard of care in reducing perinatal mortality at St. Francis Hospital, Nsambya
Objectives of the study:
Broad study objectives:
To evaluate the role of third trimester modified biophysical profile scan in predicting fetal outcome among pregnant mothers at St. Francis Hospital, Nsambya.
Specific study objectives:
- To determine the percentage decline in perinatal mortality following use of third trimester biophysical profile from 34 to 40 weeks at St. Francis Hospital, Nsambya.
- To determine if use of third trimester BPP scan improves prediction of perinatal outcome more than the current standard of care at St. Francis Hospital, Nsambya.
- To determine the fetal outcome of pregnancies done modified BPP and those who received current standard of care at St. Francis Hospital, Nsambya.
Hypothesis:
The hypothesis of the study is that performing third trimester modified biophysical profile scan between 34 and 40 weeks compared to standard of care is associated with a 16 percent reduction
Detailed description
Randomization:
Eligible participants will be randomly allocated to one of the two study groups (modified biophysical profile scan arm or current standard of care arm) by an independent statistician who will not be involved in data analysis. The independent statistician will generate a randomization register consisting of the sequential study numbers but without the allocated study group. The register will be held at the enrollment clinic and patients who will be eligible for enrollment will be assigned the next available number on the register until the required sample size is reached. The principal investigator will identify a secure room from where opaque envelopes containing the different study arms will be kept. Participants will pick envelopes randomly from the pool of envelopes to obtain the study arm to which they automatically belong.
Blinding:
The study will be open label but only blinding the allocation at study entry.
Randomization concealment
No one including the independent statistician will know the study arm at the point of randomization. Because the intervention is not blinded, the rest of the study team including the principle investigator will get to know the study arm after the women have been randomized.
Sample size:
The use of fetal biophysical profile has been associated with 61 to 79 percent reduction in fetal mortality and morbidity. The incidence of perinatal death (Macerated still birth, Fresh stillbirth \& Early neonatal death) in 2016 was 2% of the annual total deliveries, giving a perinatal mortality ratio of 20 per 1000 live birth at St. Francis Hospital Nsambya. The following assumptions will be made in the determination of the minimum sample size; the current standard of care of mothers attending antenatal care at Nsambya Hospital as defined by World health organization (WHO) in 2016 will detect up to 79% of fetal outcome, while performing modified biophysical profile scan proposed in this trial will increase this proportion to 95% at the 5% level of significance, and power of 80. Using a formula for comparing two proportions from Medical statistics book by Betty Kirkwood and Jonathan Sterne, 2003; The minimum sample size , Where this gives an increase in prediction of 16%. V= the Standard normal deviate at 95% Confidence (from Z-statistical tables, V=1.96), U =Standard Normal Deviate at 80% Power (power =1-β) ( from Z-statistical tables, u=0.84). Substituting, = 89.2 women. This gives approximately 90 women in each group and a total sample size of 180 women. Assuming a non-response proportion of 10%, the sample size will be increased by 10% to 198 women (99 in each group).
Data management and handling:
The study data will be entered using Microsoft (MS) access (MS-ACCESS, 2016) and will be double checked and validated before being uploaded into the database. The data entry screens will incorporate a number of range checks and logical skips as appropriate. Data stored in the database will be checked for missing or unusual values (range checks) and checked for consistency within participants. If any such problems are identified the problematic questionnaire will be returned to the clinic for checking and confirmation or correction, as appropriate. The amended version will be returned to the data entrant for correct entry into the database.
Statistical analysis plan:
Participant socio-demographics and other characteristics will be summarized using counts and percentages and by study group, for categorical variables and means and standard deviation for continuous variables. The analysis will be by intention to treat (ITT). I will calculate the mortality rate as the number of death divided by total time of follow up. The mortality will be further stratified by the study group (intervention vs standard of care). Rate ratio comparing the trial groups will be estimated by fitting a cox regression model. If there are any imbalance in the important participant characteristics at baseline, adjustment for these will be performed by fitting cox regression models. A similar analysis will be performed for the secondary outcomes.
Data quality control:
The study team will be trained on data collection and handling procedures. A pretest in form of completing the study questionnaire as well as a dry run will be done before the commencement of the actual data collection. To ensure proper data management, the data collectors will be trained in data management and will complete certification process of Good Clinical Practices (GCPs). Data collectors will be health workers who work in the Obstetrics department, they will not be directly involved in the management of mothers in Antenatal clinic or inpatient wards to avoid observation bias if he/she was among the people managing these patients. All interviews will be conducted in the language understood by the study participants.
Data monitoring committee:
There will be a data monitoring committee established to monitor the quality of data being collected. This three member committee will be selected from outside the study site. They will be people with experience in monitoring trial data. They will sit every 3 months or as requested by the institutional review board of St. Francis Hospital Nsambya.
Data protection and confidentiality:
The study questionnaires will not bear participant names but rather identification numbers. The study team will ensure the data is not accessible to anyone else by 1) keeping the paper questionnaires under lock and key 2) using passwords to secure the study database. The team will also ensure that the study data is used for only the purpose approved by the ethics committees.
Ethical considerations:
The study will seek ethical approvals from the Institutional Review Board (IRB) of Nsambya Hospital. The Hospital authority will also be requested for permission to have access to the pregnant women in the study clinic. Participants will be allowed to withdraw from the study whenever they so wish. All the data collected will be treated with utmost confidentiality.
STANDARD OPERATING PROCEDURE (SOP) FOR ENROLLMENT/SCREENING VISIT
- The pregnant women are received, welcomed and briefed about the services by the midwife in the Antenatal clinic registration desk.
- The midwife registering at the reception will identify pregnant women who are between 34 to 40 weeks gestation.
- If one is attending for the first time but within the gestational age of interest, then the base line investigations will be done (Complete blood count, blood grouping, HIV, Urinalysis, Gestational diabetes mellitus screening, Syphilis test and Hepatitis B test).
- For those who have been booked already, the study midwife will check the antenatal card and results of the above. If any is missing, a request would be written and sample taken.
- Body weight and blood pressure will be measured at this point.
- Immediately after receiving the antenatal card, the pregnant women will be directed to the waiting area from where routine antenatal health education and information about the study is given by one of the Antenatal clinic and study Midwives.
- After providing information about the study, the study midwife will duly consent the mother and assign the randomization number sequentially from the register to those who volunteer to participate in the study.
- The pregnant mother is accompanied by midwife to the study office (Room 9) from where the PI will request the mother to randomly pick an opaque envelope from the randomization pack to determine the study arm of this study participant.
- The study arm will be known by the study team at this point and clearly documented in the patient's antenatal card.
- The enrolled mothers will be examined by the study doctor or midwives and findings documented in the Antenatal card and Case report form (CRF).
- The mothers in the modified Biophysical profile ARM will be required to undergo a modified biophysical profile scanning free of charge and the results of the scan documented in the CRF.
- The mother will bring back the results of the scan and blood tests to the study doctor. The study doctor will document the above results on the CRF. He will give an appropriate follow up date and indicate the date for performing the next modified biophysical profile (mBPP) scan.
- The registers and all other documents are taken to the research office at the end of the day by the Clinical Trial Midwife. All completed CRFs are scrutinized by the Trial PI and signed. If the Trial midwife detects errors in the CRFs, He or she will put a Note to the file accordingly as per the data management SOP.
- The completed file folders will then be placed in the rack for not entered data. The entry into the data base will then be as per the data management SOP.
STANDARD OPERATING PROCEDURE FOR MISSED VISITS
- The pre-enrollment and enrollment registers will have the scheduled appointments for each study participant.
- Any study participant who fails to honor an appointment will be followed up with a phone call the next day to ascertain the reason why she did not turn up and encouraged to come. If she fails to turn up, a second phone call will be made and another appointment fixed.
- A study participant who fails to honor her appointments and fails to respond to the above follow up would be considered as one lost to follow up.
STANDARD OPERATING PROCEDURE FOR TRACING MOTHERS WHO HAVE GONE PAST THEIR EXPECTED DATE OF DELIVERY (EDD) / DELIVERED ELSEWHERE
- Each week, mothers who have not delivered at the study site are traced from the CRF/date of delivery list by the principle investigator.
- The study participant is given a phone call and advised to visit the study site if not delivered to see the Doctors to assess her and plan for her delivery. If the person has already delivered from elsewhere, information regarding delivery is obtained and entered into the CRF.
STANDARD OPERATING PROCEDURE FOR UNSCHEDULED VISIT
- Participants will be encouraged to come in every time they have a problem direct to Antenatal clinic Room 9 or labor ward in case it's after 5.00 pm where a doctor reviews her and the clinical trial coordinator is informed.
- Participant will be seen by the Clinical Trial Investigator in the Antenatal Clinic on Monday- Friday from 8:00am-5:00pm.
- After 5:00pm, during weekends, public holidays, Participant will report to the Labor ward and be seen by the Doctor on Duty and managed appropriately.
STANDARD OPERATING PROCEDURE FOR DOCUMENTING DELIVERY AND FETAL OUTCOME
- Identification of study Participants who present in labor ward will be done by any of the labor ward midwives by asking for their antenatal card bearing the sticker and by asking whether the participant has been in the study. This process will be for both mothers in labor and those scheduled for Cesarean section.
- The labor ward midwives will then inform one of the research midwives about the study participant. The research midwife will then verify the antenatal records and place an appropriate sticker on the patient file for easy identification. The study midwife will duly inform the Principle investigator.
- For mothers who will undergo an elective or emergency cesarean section, the birth outcome will be documented from the post natal wards.
- Immediately after delivery of the baby, the study midwife will document the birth outcome in the CRF which placed in a box file awaiting data cleaning and entry.
- The above procedure will be followed for delivery during day, night and over the weekend.
STANDARD OPERATING PROCEDURE FOR DATA MANAGEMENT
- The Case report form (CRF) will be assessed by the Clinical Trial Principle Investigator daily for accuracy, legibility and completeness.
- The CRFs will then be filled, placed in the respective file folder and then placed in the rack for not entered data.
- Only authorized study staffs (the Data Clerks, Principal Investigator, statisticians) are allowed to have access to the database.
- Every afternoon, the Data Clerk will pick the CRFs from the box file of not entered data and then enter it into the database (Epi-data)
- At the end of the day, all data will be saved and backed up on a flash disk or External Hard Drive.
- After the CRFs have been entered into the database, they will be placed in the Box file for entered data for proper storage by one of the Data Clerks.
STANDARD OPERATING PROCEDURE FOR COMPLETING CASE REPORT FORM (CRF)
- CFR must be filled with a ball-point-black ink.
- Capital letters must be used in all entries of the CRF. The dates that are not known will be represented with value 11/11/1111.
- The Principle investigator and the Trial Coordinator will write Not applicable on all different CRF for non obtainable information whether numerical or non numerical.
- Corrections on CRF will be done by the person who has filled in that CRF.
- Corrections will be done by crossing out the wrong entry with a single line, then writing the correct entry alongside/above/under the wrong entry.
- After correction, a date will be placed alongside the correction as well as the initials of the Research staff.
- A note to file will be placed on that page of the CRFs to explain the correction by the Research staff and confirmed by the Principal investigator
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Eligible pregnant women at 34 to 40 weeks gestation will be randomized to interventional group (Biophysical profile scanning) or to a control group receiving the current standard of care
| Arm | Type | Receives |
|---|---|---|
| Modified Biophysical Profile scan | Experimental | Other: Modified Biophysical Profile scanParticipants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea. |
| Current standard of care | No intervention | –The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Viable singleton pregnancy
- Gestational age between 34 to 40 weeks based on reliable date of onset of last normal menstrual period or earliest dating by ultrasonography.
- Willing to be followed up
Key exclusion criteria (5 listed)
- Mother with diagnosed fetal malformations
- High-risk pregnancies (Hypertensive disorders of pregnancy, Diabetes mellitus, multiple pregnancies, Sickle cell disease, Heart disease).
- Inability to consent (e.g. psychiatric conditions or very ill requiring hospitalization).
- Intrauterine fetal death in the current pregnancy
- Presently ill with a medical condition requiring admission to hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Modified Biophysical Profile scanModified biophysical profile scan to be done in third trimester for eligible pregnant mothers | Other | Modified Biophysical Profile scan |
Primary outcome
Perinatal death
Time frame: At delivery of the newborn
Reduction in the proportion of perinatal death will be measured for the two arms of the study to ascertain whether modified biophysical profile can predict perinatal mortality. Perinatal mortality will be measured as death of the new born within the first 7 days of life. The gestational age considered is after 28 weeks of amenorrhea consistent with the health system capacity of the host country and the study hospital
3 secondary outcomes
APGAR score
Time frame: at birth
Neonatal intensive care unit (NICU) admission
Time frame: Immediately after birth
Cesarean section due to fetal condition
Time frame: At delivery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2019.
- Individual participant dataSharing planned: Yes. Only data necessary for publication will be shared
Related trials for Perinatal Death
Not yet recruiting
e-Perinatal Butterfly: An Embedded Study for Parents Experiencing Perinatal Loss
Depressive Symptoms, Perinatal Loss
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Not yet recruiting
Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia
Neonate, Asphyxia
Enrolling by invitation
Pregnancy in the Context of Urbanicity and Climate Change. The Overall Aim of the Project is to Co-create, Implement, and Test New Clinical Guidelines in Order to Improve the Quality of Care in Antenatal Clinics in the Context of Urbanisation and Climate Change in Dar es Salaam, Tanzania.
Perinatal Death, Hypertension, Pregnancy-Induced
Recruiting
Walk With Me (WWM) for Perinatal Grief
Grief, Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew Odur, MBChB, DPPM principal investigator
St. Francis Hospital Nsambya
Romano Byaruhanga, MMed, PhD study chair
St. Francis Hospital Nsambya
Rita Nassanga, MMed study chair
St. Francis Hospital Nsambya
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Modified Biophysical Profile scan in people with Perinatal Death and Third Trimester Modified Biophysical Profile Scan, run by Dr Andrew Odur at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perinatal death (time frame: At delivery of the newborn). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2019.